What is HC Wainwright’s Forecast for Myomo FY2026 Earnings?

Myomo, Inc. (NYSEAMERICAN:MYO) – Research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for shares of Myomo in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of $0.00 for the year, down from their previous estimate of $0.05. HC Wainwright has a “Buy” rating and a $9.50 price target on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s FY2028 earnings at $0.42 EPS and FY2029 earnings at $0.60 EPS.

MYO has been the subject of several other reports. Craig Hallum lifted their price target on Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday. Alliance Global Partners reissued a “buy” rating on shares of Myomo in a report on Tuesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $9.25.

Myomo Stock Up 2.4 %

NYSEAMERICAN:MYO opened at $5.19 on Friday. The company has a market cap of $157.00 million, a P/E ratio of -22.57 and a beta of 1.68. Myomo has a 1-year low of $2.51 and a 1-year high of $7.17.

Hedge Funds Weigh In On Myomo

A number of institutional investors have recently modified their holdings of MYO. GSA Capital Partners LLP raised its holdings in shares of Myomo by 60.8% during the 3rd quarter. GSA Capital Partners LLP now owns 103,342 shares of the company’s stock worth $414,000 after buying an additional 39,085 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in shares of Myomo during the 3rd quarter worth $401,000. Jane Street Group LLC acquired a new position in shares of Myomo during the 3rd quarter worth $65,000. XTX Topco Ltd acquired a new position in shares of Myomo during the 3rd quarter worth $149,000. Finally, Barclays PLC acquired a new position in shares of Myomo during the 3rd quarter worth $36,000. Institutional investors and hedge funds own 44.99% of the company’s stock.

Insider Buying and Selling at Myomo

In other Myomo news, Director Thomas F. Kirk purchased 7,400 shares of the stock in a transaction dated Thursday, March 13th. The stock was bought at an average price of $5.00 per share, with a total value of $37,000.00. Following the acquisition, the director now owns 255,933 shares of the company’s stock, valued at approximately $1,279,665. This represents a 2.98 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Micah Mitchell sold 48,000 shares of the business’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $5.16, for a total value of $247,680.00. Following the transaction, the insider now directly owns 140,572 shares of the company’s stock, valued at $725,351.52. This trade represents a 25.45 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.54% of the company’s stock.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.